Emerging role of GLP-1 receptor agonists in the treatment of obesity

Código QR

Emerging role of GLP-1 receptor agonists in the treatment of obesity

Lisa M Neff1, Robert F Kushner21Division of Endocrinology, Metabolism, and Molecular Medicine, 2Division of General Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USAAbstract: The prevalence of obesity has increased dramatically in recent decades,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Neff LM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	obesity GLP-1 exenatide liraglutide Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/c3a463ab4c97492ba35bd936794ad4f1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
por: Courtney H, et al.
Publicado: (2017)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Lisa M Neff, et al.
Publicado: (2010)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
por: Knop FK, et al.
Publicado: (2010)

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
por: Chudleigh RA, et al.
Publicado: (2020)

An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method
por: Martin AA, et al.
Publicado: (2016)

Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
por: Bastin M, et al.
Publicado: (2019)

Clinical Impact of Liraglutide as a Treatment of Obesity
por: Alruwaili H, et al.
Publicado: (2021)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao Q, et al.
Publicado: (2016)

Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chee&nbsp;W Chia, et al.
Publicado: (2009)

Associations of TCF7L2 rs11196218 (A/G) and GLP-1R rs761386 (C/T) Gene Polymorphisms with Obesity in Chinese Population
por: Xu T, et al.
Publicado: (2021)

Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
por: Saunders WB, et al.
Publicado: (2016)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Seewoodhary J, et al.
Publicado: (2010)

Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype
por: Toomas Jagomäe, et al.
Publicado: (2021)

GLP-1 mediates the modulating effect of thymoquinone on feeding behaviors in diabetic rats
por: Lee SP, et al.
Publicado: (2019)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011)

Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
por: Stolar MW, et al.
Publicado: (2013)

Effects of liraglutide on lipolysis and the AC3/PKA/HSL pathway
por: Li Z, et al.
Publicado: (2019)

Essential Role Of High Glucose-Induced Overexpression Of PKCβ And PKCδ In GLP-1 Resistance In Rodent Cardiomyocytes
por: Pan X, et al.
Publicado: (2019)

Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials
por: Orme ME, et al.
Publicado: (2017)

A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives
por: Reed J, et al.
Publicado: (2021)

Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo
por: Yanbin Dong, et al.
Publicado: (2021)

Liraglutide and Insulin Have Contrary Effects on Adipogenesis of Human Adipose-Derived Stem Cells via Wnt Pathway
por: Liu H, et al.
Publicado: (2020)

Dysregulation of DPP4 Is Associated with the AMPK/JAK2/STAT3 Pathway in Adipocytes Under Insulin Resistance Status and Liraglutide Intervention
por: Cheng F, et al.
Publicado: (2019)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
por: Thompson AM, et al.
Publicado: (2016)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
por: Campbell RK, et al.
Publicado: (2010)

A paradigm shift for the prevention and treatment of individual and global obesity
por: Slyper AH
Publicado: (2018)

Barberry in the treatment of obesity and metabolic syndrome: possible mechanisms of action
por: Firouzi S, et al.
Publicado: (2018)

Glucagon-Like Peptide 1 Attenuates Lipotoxicity-Induced Islet Dysfunction in ApoE–/– Mice
por: Liu F, et al.
Publicado: (2020)

Weight loss medications in Canada – a new frontier or a repeat of past mistakes?
por: Wharton S, et al.
Publicado: (2017)

The role of Leu260Phe polymorphism of the receptor gene to GLP-1 incretin in the pathogenesis of diabetes type 2 diabetes with obesity
por: Daria A. Skuratovskaia, et al.
Publicado: (2019)

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
por: Gurung T, et al.
Publicado: (2015)

COVID-19 and Obesity: Epidemiology, Pathogenesis and Treatment
por: Zhu X, et al.
Publicado: (2020)

Obesity and brain illness: from cognitive and psychological evidences to obesity paradox
por: Monda V, et al.
Publicado: (2017)

Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice
por: Morieri ML, et al.
Publicado: (2020)

The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
por: Sonia A Tucci, et al.
Publicado: (2010)

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Publicado: (2009)

Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
por: Hurt RT, et al.
Publicado: (2018)

Is obesity in women protective against osteoporosis?
por: Migliaccio S, et al.
Publicado: (2011)

Clinic, Anthropometric And Metabolic Changes In Adults With Class III Obesity Classified As Metabolically Healthy And Metabolically Unhealthy
por: Loureiro LM, et al.
Publicado: (2019)

Obesity and the development of type 2 diabetes: the effects of fatty tissue inflammation
por: Schuster D
Publicado: (2010)